

Bacterial Uropathogens Isolates and Antibigrams in Children Under 5 Years of Age

Mohamed Alkhatim Alsammani, Mohamed Issa Ahmed, Nahla Farouk Abdelatif

Department of Medical Biochemistry, College of Applied Medical Sciences, Qassim University, Bahri, Sudan

Corresponding author: Mohamed Alkhatim Alsammani, MD. Department of Medical Biochemistry, College of Applied Medical Sciences, Qassim University, Bahri, Sudan.

ABSTRACT

Background: Childhood urinary infections are among the most common febrile illnesses occurring during this period with varying susceptibility to antibiotic. **Aim:** The aim of this study was to identify uropathogens responsible to for urinarytract infection (UTIs) in children less than 5 years of age, and determine the antibiograms of the isolates to commonly used antibiotics. **Patients and methods:** Hundred and four children (2 months - 5 years old) seen at the Gadarif Teaching Hospital from January 2012 and December 2013 were evaluated. A urine specimen was obtained by a plastic bag with an adhesive backing around an opening or by direct voiding into sterile container. Urine was examined microscopically and those with significant pyuria and bacteruria were further cultured and microorganisms were identified and tested for antimicrobial susceptibility. **Results:** Out of 304 children suffering from UTIs; 145(47.7%) had significant pyuria of them; 54(17.8 %) had positive bacterial growth. The frequency of sex and residency were almost the same. *E. coli* (42.6%) was the most common uropathogen, sensitive to ciprofloxacin (91.3%), followed by *Pseudomonas aeruginosa*(29.6%) sensitive to Ciprofloxacin (75%)and Norofloxacin (68.8%),*Klebsiellapneumoniae*(18.5%) sensitive to Ciprofloxacin and Norofloxacin and Nalidixic acid (90%) and *Proteus mirabilis* sensitive to Ciprofloxacin and Norofloxacin (90%), Amoxicillin / clavulanic acid (Augmentin(80%). **Conclusion:** The most common uropathogens were *E. coli*, *Pseudomonas aeruginosa*,*Klebsiellapneumoniae*, and *Proteus mirabilis*. Ciprofloxacin is the recommended initial empirical therapy while awaiting the culture and sensitivity results.

Keywords: pediatrics, urinary tract infection, antimicrobial, sensitivity, resistance.

1. INTRODUCTION

Urinary tract infection is the most common febrile illness in pediatric second to otitis media and pharyngitis. It accounted for 10% of all febrile illnesses in children (1, 2, 3). Long-term complications of urinary tract infection in children include unilateral renal parenchymal defect and unilateral kidney retarded growth. The glomerular filtration rate and blood pressure do not change indicating a very low for serious renal damage (4).

It is more common in preterm babies (4-25%) than term ones (1%) (5). In early life, it is more common in males than female then it decline rapidly in the prepubertal life girls experienced more episodes of UTIs than males, 8% compared to 2% respectively (6, 7).

Escherichia coli for many years remain the most common isolates causing UTI in children (60–92%). Other common organisms include *Klebsiella*, *Proteus*, *Enterobacter spp.* and *Enterococcus* (8-10). Diagnosis of UTI may in children is simple usually urine analysis and cultures are enough to establish the diagnosis. The most difficult task is to established appropriate therapy. The development of multidrug resistance strains makes treatment issue among the most controversial issues in children.

In Africa, UTIs in children is a common and complex problem due to co-infection with other febrile illnesses (11). High frequency rate of infection was reported by

many authors due to co-existence of multiple risks factors. In Sudan, no prior studies on UTIs in children were conducted. The aim of this study was to identify uropathogens responsible for urinary tract infection in children fewer than 5 years of age, and determine the antibiograms of the uropathogens to commonly used antibiotics. Moreover, to provide the foundation for prevention programs, and making policy decisions.

2. METHODS AND SUBJECTS

This prospective cross-sectional study was conducted at Gadarif Teaching Hospital, in Gadarif State, Eastern Sudan, during the period from June 2011 to June 2012. It is the biggest hospital of the state and there are 800 beds to maintain health services for the whole Gadarif State. The study was approved by the Hospital Ethical committee.

A total of 304 children under 5 years of age who fulfilled criteria for case definition of UTI were included in the study. Inclusion criteria were children under 5 years of age who suffered from (dysuria), (fever and dysuria), (dysuria and vomiting), (Dysuria, fever and vomiting), (Polyuria and suprabubic pain), (Fever), (Fever and vomiting), (Fever and diarrhea), (Fever, vomiting and diarrhea), (Vomiting), (Vomiting and diarrhea) or (Diarrhea) were eligible to be enrolled in the study (12). Children excluded

Isolates	Antibiotics											
	Ciprofloxacin %			Norofloxacin %			Nalidixic acid%			Nitrofurantoin%		
	S	I	R	S	I	R	S	I	R	S	I	R
E.coli	87	4.3	8.7	91.3	0.0	8.7	69.6	4.3	26.1	73.9	8.7	17.4
Ps.aeruginosa	75	18.8	6.3	68.8	18.8	12.5	25	6.3	68.8	25	0.0	75
K.pneumoniae	100	0	0	100	0	0	90	10	0	0	0	100
Pr.mirabilis	100	0	0	100	0	0	60	20	20	40	60	0

Table 1a. Uropthogens and their susceptibility to antimicrobials agents in children with urinary tract infection

Isolates	Antibiotics											
	Augmentin %			Co-trimoxazole%			Cephalexin%			Ceftriaxone%		
	S	I	R	S	I	R	S	I	R	S	I	R
E.coli	8.7	0.0	91.3	0	0	100	4.3	0.0	95.7	69.6	17.4	13
Ps.aeruginosa	31.3	12.5	56.2	31.3	6.3	62.5	12.5	6.3	81.2	6.3	50	43.8
K.pneumoniae	20	0	80	10	0	90	10	0	90	30	10	60
Pr.mirabilis	80	20	0	20	20	60	20	20	60	40	20	40

Table 1b. Uropthogens and their susceptibility to antimicrobials agents in children with urinary tract infection

from the study, were those already on antibiotic or known to suffer from other underlying conditions.

2.1. Specimens' collection

The urine sample was collected by two different techniques. For children less than 3 years of age the specimens were collected by a disposable apparatus consisting of a plastic bag with an adhesive backing around an opening that can be fastened to the perineal area or around the penis to permit direct voiding into the bag .The urethral area was cleaned thoroughly before applying the collection bag. The specimen bag was carefully removed, and the urine transferred to a sterile urine container. Then the collected urine was analyzed immediately (Fischbach and Dunning , 2004) (13). For children above the age of 3 years 3-5 ml of urine were collected into sterile container.

2.2. Urine examination

Urine samples were centrifuged at 2000 revolution per minute for 5 minutes. Wet film of urine deposits were microscopically examined for pus cells, RBCs, crystals, cast, bacterial cells. Finding of more than 5 white blood cells per high-power field in centrifuged fresh urine was considered a satisfactory positive screening test for UTI (15).

Semi-quantitative method was done by using a calibrated loop (0.001ml) of un centrifuged urine , a loopfull was spread on Cystine lactose electrolyte deficient (CLED) agar .This CLED was incubated aerobically over night at 37° C if no growth further incubation for 48 hours, the growth of 100 colony forming units by this method indicates the presence of 10⁵ bacteria per ml of urine (Michael L et. al, 2004) [16] . The bacterial growth estimation of (10⁵)bacteria per ml or more was considered UTI; A count of 10.000–49.000bacteria/ ml was considered significant with a signs of acute infection (presence of pyuria). The count of 10 colonies and above with presence of pyuria indicate significant bacteriuria.

Bacteriological Identification for significant specimen on presumptive colony was identified using: colonial morphology (16), gram stain (17), and biochemical test s such as: indole, citrate, oxidase, H2S production, MR-VP, lactose fermentation, urea hydrolysis, gas production, catalase, coagulase previously discuss by Bartet al. (18).

2.3. The Analytical Profile Index (API) systems

Analytical Profile Index (API-20E) system was performed for confirmation of identification as previously mentioned by (Ahmed MI, 2012) to identify members of the family Enterobacteriaceae and associated organisms (BioMerieux, Inc. Hazelwood, MO., France).

2.4. Antimicrobial susceptibility test

The “**disc diffusion method**” were employed by standardize filter paper discs impregnated with fixed amounts of antimicrobial drugs.

3. RESULTS

A total of 304 (100%) children suffering from UTIs with the mean age 1.97±1.061 years were included in this study. The majority of these children 203 (66.7 %) were less than two years of age, and more than half of them were male 174 (57.2%). Significant pyuria and bacteriuria was detected in 47.7 %(n=145) of the total studied subjects; in 250 (82.2%) no potential pathogens were isolated. The frequency of UTI was also equal in urban and rural settings (51% vs. 49%). Of them; only 17.5% (n=54) had positive bacterial growth. The majority 46.3 % (n=25) of subjects were less than 1 year of age, followed by age group 1 to 2 years 20.4%,and 16.7% for both 2 to 3 and more than 3 years of age.

The most common bacterial isolates were *Escherichia coli* - 23 (42.6%) followed by *Pseudomonas aeruginosa* -16 (29.6%), *Klebsiellapneumoniae* - 10(18.5%), and *Proteus mirabilis* - 5 (9.3%) as identified by conventional biochem-




Figure 1. Types of bacterial isolates




Figure 2. Distribution of uropathogens in males according to age group




Figure 3. Distribution of uropathogens in females according to age group

ical tests Figure 1. Furthermore, the rapid and accurate test of identification organisms (API identification system) for *Enterobacteria* used to confirm the conventional identification methods results showed typical results.

In males, the predominant uropathogens during the first year of life was *Klebsiella pneumonia* 46.7 %, while *E.coli* and *Proteus mirabilis* constituted 13.3% of isolates for each, after the first year of life the *Escherichia coli* isolates predominated 100% Figure 2.

In females, both *Escherichia coli* and *Pseudomonas aeruginosa* were the predominating isolates up to 5 years with few *Proteus mirabilis* infection Figure 3.

3.1. Antimicrobial Susceptibility

The antimicrobial susceptibility of all isolates is shown in Tables 1a and 1b. *E. coli* isolates was resistance against; Augmentin 91.3%, cotrimoxazole 100%, Cephalexin 95.7%, and Nalidixic acid 26.1%. However *E. coli* isolates were highly susceptible to Norofloxacin 91.3%, ciprofloxacin 87% and Nitrofurantoin 73.9% intermediate sensitivity is shown on the tables.

Ps.aeruginosa was shown resistant against; Cephalexin 81.2%, Co-trimoxazole 62, 5%, Nitrofurantoin 75%, Augmentin 56.2% and Ceftriaxone 43.8%. On other hand *Ps.aeruginosa* isolates were susceptible; to Ciprofloxacin 75%, and norfloxacin 68.8%.

Both *K.pneumoniae* and *Pr.mirabilis* were high susceptible; to ciprofloxacin (100%), and (Norofloxacin) 100%. *K.pneumoniae* isolates were 90% sensitive to Nalidixic acid compared to 60% for *Pr.mirabilis*. *K.pneumoniae* isolates showed 100% resistance to Nitrofurantoin.

4. DISCUSSION

In this study, of all subjects with significant pyuria (145, 47.7%), 54 (17.8%) had positive bacterial growth. The risk of developing UTIs in these children under was almost

equal among males (51.9%) and females (48.1%) and rural and urban residency was similarly affected. The majority of subjects 36 (66.7 %) were less than two years of age. *E. coli* (42.6%) was the most predominant uropathogen, sensitive to ciprofloxacin (91.3%), followed by *Pseudomonas aeruginosa* (29.6%) sensitive to Ciprofloxacin (75%) and Norfloxacin (68.8%), *Klebsiellapneumoniae* (18.5%) sensitive to Ciprofloxacin and Norfloxacin and Nalidixic acid (90%) and *Proteus mirabilis* sensitive to Ciprofloxacin and Norfloxacin (90%), Amoxicillin / clavulanic acid (Augmentin) (80%).

Furthermore, the study showed that the incidence of first episode of UTIs was similar in both sexes in during the first year of life and thereafter, females had the higher incidence of UTIs than males. Studies from Sweden have shown similar findings (19, 20).

This study documented a high frequent occurrence of urinary tract infections (17.8%), and bacteremia among febrile under-fives attending Maternity and Children hospital Gadarif, Eastern Sudan. This finding does not represent the true prevalence of UTIs in Gadarif district because the nature of the study was a hospital-based, only patients with severe disease and those who live nearby reported to the hospital while those living far or have financial constraints, or lack of transportation. Empirical treatment of all fever with antibiotics and antimalarial is a common practice in the developing nations. A higher prevalence rate (20.3%) of UTIS was reported in Africa (21). Frequency of UTIs in the developing countries is very high than 3.3% and 9% rates quoted from developed countries (22, 23).

It has been found that the earlier the development of UTIs in life, the higher chance of developing recurrent UTIs, furthermore, the risk of recurrent UTIs increased significantly when the first infection is caused by a non-*E. Coli* strain (25). In this study, we found that the dominant uropathogen was *E. coli* followed by *Pseudomonas aeruginosa*, *Klebsiellapneumoniae* and *Proteus mirabilis*. In Sudan, a similar study conducted on adult populations showed that *E. coli* of least occurrences (6%), while the dominant organism was *P. aeruginosa* (37%) (26).

Our findings are in agreement with some previous studies, which have shown that *Escherichia coli* were the commonest organism isolated from urine samples (24, 27). Furthermore, and in a study it was found that it accounted for 75% of all UTIs in all pediatrics of all age group followed by *Klebsiellapneumoniae*, *Proteus mirabilis* and *Pseudomonas aeruginosa* (28, 22). A recent study examined the pathogens and their susceptibility in the first episode of UTIS showed that 96.1% of the isolate were *Escherichia coli* with high susceptibility to aminoglycosides, ciprofloxacin and nitrofurantoin; third generation cephalosporins, and low susceptibility to cephaloxin (29).

E. coli isolates in this study were highly sensitive (near 100%) to ciprofloxacin, Norfloxacin, and nalidixic acid. Unfortunately, it showed high resistant to commonly used antibiotics (Augmentin, Cephalexin and -trimoxazole) (near 100%). Similar findings from Tanzania reported that *E. coli* is the dominant organism as a cause of UTIs in children under-fives, and it is sensitive to fluoroquinolones and resistant to third- and fourth-generation cephalo-

sporin's (1). Similar studies were concluded in Marrakech [30] and in Kashmir (31) concluded that *Escherichia coli* were the most predominant isolate, followed by *Klebsiellapneumoniae* and *Pseudomonas aeruginosa*. However, they differ in the antibiotic sensitivity pattern, in Marrakech third generation cephalosporin's and aminosides kept their effectiveness on the majority of isolates were the most effective treatment while, in the latter study, *E. coli* isolates were fully sensitive to ofloxacin, and cefuroxime. The high sensitivity to ciprofloxacin In this study may be explained by the fact that it is not one the commonly used drug for children due to their questionable safety in children.

The development of multi-drugs resistance (MDR) to commonly used antibiotics in the developing world could be due to drug misuse, this misuse over time, will lead to greater levels of mutation in bacteria, leading to high levels of bacterial resistance. Moreover, antibiotics are used as growth promoters to control infectious disease may lead to the development of MDR due to change in the genetic composition of bacteria.

In this study, *Pseudomonas aeruginosa* was found to be resistant to many antibiotics, and only appreciable susceptibility was found with Ciprofloxacin and Norfloxacin (near70%). Many studies have demonstrated that *Pseudomonas aeruginosa* is becoming multi-drug resistant organism (31, 32). Furthermore, results from United States and European hospitals indicated that *Pseudomonas aeruginosa* exhibited lower susceptibility rates to many antimicrobial drugs in Europe compared to) compared to USA(33-35). There is no report on current literature showed there are satisfactory antimicrobials that provided a satisfactory coverage for this organism. This means that treatment of UTI in the absence of susceptibility will results in long-term complications of UTIs and the emergence of multi-resistant organisms.

Antibiotic resistance rates in uropathogens are rapidly growing, especially with regard to *E. coli* infections. For all uropathogens culture and sensitivity of the isolates remains the only solution to decrease multi-drug resistance strains, and it should be done as a routine before advocating the therapy. Antibiotic abuse is of serious concern in the developing world, and a restriction of their uses in the community to a retard development of further drug resistance is important. Drug-resistant *E. coli* are readily acquired through the food and water; therefore, public and personal hygiene are the essential component of this circuit. Prescribing medications while awaiting culture may lead to increase in MDR strains. Future researchers may be able to change our practice in solving this problem.

5. CONCLUSION


The most common uropathogens were *E. coli*, *Pseudomonas aeruginosa*, *Klebsiellapneumoniae*, and *Proteus mirabilis*. Ciprofloxacin is the recommended initial empirical therapy while awaiting the culture and sensitivity results.

CONFLICT OF INTEREST: NONE DECLARED.

REFERENCES

1. Wolff O, MacIennan C. Evidence behind the WHO guidelines: hospital care for children: what is the appropriate empiric antibiotic therapy in uncomplicated urinary tract infections in children in developing countries? *J Trop Pediatr.* 2007; 53(3): 150-152.
2. Harmsen M, Wensing M, Braspenning JC, Wolters RJ, van der Wouden JC, Grol GPTM, Management of children's urinary tract infections in Dutch family practice: a cohort study. *BMC Fam Pract.* 2007; 8: 9.
3. Alper BS, Curry SH. Urinary tract infection in children. *Am Fam Physician.* 2005; 72(12): 2483-2488.
4. Hannula A, Perhomaa M, Venhola M, Pokka T, Renko M, Uhari M. Long-term follow-up of patients after childhood urinary tract infection. *Arch Pediatr Adolesc Med.* 2012; 166: 1117-1122.
5. Sastre JB, Aparicio AR, Cotallo GD, Colomer BF, Hernandez MC. Urinary tract infection in the newborn: clinical and radio imaging studies. *Pediatr Nephrol.* 2007; 22(10): 1735-1741.
6. Bauer R, Kogan BA. New developments in the diagnosis and management of pediatric UTIs. *Urol Clin North Am.* 2008; 35(1): 47-58.
7. Masson P, Matheson S, Webster AC, Craig JC. Meta-analyses in prevention and treatment of urinary tract infections. *Infect Dis Clin North Am.* 2009; 23(2): 355-385.
8. Akram M, Shahid M, Khan AU. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J NMC Hospital. Aligarh, India. *Ann Clin Microbiol Antimicrob.* 2007; 6: 4.
9. Chakupurakal R, Ahmed M, Sobithadevi DN, Chinnappan S, Reynolds T. Urinary tract pathogens and resistance pattern. *J Clin Pathol.* 2010; 63: 652-654.
10. Lutter SA, Currie ML, Mitz LB, Greenbaum LA. Antibiotic resistance patterns in children hospitalized for urinary tract infections. *Arch Pediatr Adolesc Med.* 2005; 159: 924-928.
11. Okunola PO1, Ibadin MO, Ofovw GE, Ukoh G. Co-existence of urinary tract infection and malaria among children under five years old: a report from Benin City, Nigeria. *Saudi J Kidney Dis Transpl.* 2012 May; 23(3): 629-634.
12. Megged O. *Staphylococcus aureus* urinary tract infections in children are associated with urinary tract abnormalities and vesico-ureteral reflux. *Pediatr Nephrol.* 2014 Feb; 29(2): 269-272.
13. Fischbach FT, Dunning MB. *Urine studies and Microbiologic studies. A manual of laboratory and diagnostic tests 7th edition.* Lippincott Williams and Wilkins. 2004; 201, 503-505.
14. El Mishad AM. *Manual of practical Microbiology, 7th editon,* Alahram Commercial Press. Egypt, 2002: 112-151.
15. Dagan R, Powell KR, Hall CB, Menegus MA. Identification of infants unlikely to have serious bacterial infections although hospitalized for suspected sepsis. *J Pediatr.* 1985; 107: 855-860.
16. Michael LW, Loretta G. *Laboratory Diagnosis of Urinary Tract Infections in Adult Patients.* Clinical Infectious Diseases. 2004; 38: 1150-1158.
17. Ananthanaryan R, Jayaram P. *Textbook of Microbiology, 5th edition,* Orient Longman, India. 1997: 258-261.
18. Ochei J, Kolhatkar A. *Medical Laboratory Science Theory and Practice,* Tata McGraw-Hill Publishing Company, India. 2000: 635.
19. Bart J Knottnerus, Patrick JE Bindels, Suzanne E Geerlings, Eric P. Moll van Charante, Gerbenter Riet. Optimizing the diagnostic work-up of acute uncomplicated urinary tract infec-

- tions. *BMCF Am Pract.* 2008; 9: 64.
20. Ahmed MI. Prevalence of nosocomial wound infection among postoperative patients and antibiotics patterns at teaching hospital in Sudan. *North Am J Med Sci.* 2012; 4: 29-34.
 21. Jakobsson B, Esbjorner E, Hansson S, Ferreira C, Matos P, Monteiro T. Minimum incidence and diagnostic rate of first urinary tract infection. *Nascer e Crescer.* 2000; 9: 51-52.
 22. Marild S, Jodal U. Incidence rate of first-time symptomatic urinary tract infection in children under 6 years of age. *Acta Paediatr.* 1998; 87: 549-552.
 23. Msaki BP, Mshana SE, Hokororo A, Mazigo HD, Morona H. Prevalence and predictors of urinary tract infection and severe malaria among febrile children attending Makongoro health centre in Mwanza city, North-Western Tanzania. *Arch Public Health.* 2012; 70(1): 4.
 24. Panahi Y, MoharamzadBeiraghdar, Matinzadeh ZK, Einollahi B. The incidence of urinary tract infections in febrile children during a two-year period in Tehran, Iran. *Tropica Doctor.* 2008; 38(4): 247-249.
 25. Poulsen LL1, Bisgaard M, Son NT, Trung NV, An HM, Dalsgaard A. Enterococcus and Streptococcus spp. associated with chronic and self-medicated urinary tract infections in Vietnam. *BMC Infect Dis.* 2012 Nov; 23: 12: 320..
 26. Okwara FN, Obimbo EM, Murila FV. Bacteremia, UTI and malaria in hospitalized febrile children in Nairobi. Is there an association? *East Afr Med J.* 2004; 81: 47-51.
 27. Park SI, Song SH, Lee C, Kim JW, Kim KS. Bacterial pathogens in first febrile urinary tract infection affect breakthrough infections in infants with vesicoureteral reflux treated with prophylactic antibiotics. *Urology.* 2013 Jun; 81(6): 1342-1345.
 28. Ahmed MI, Mohsin S. Pattern of Nosocomial Urinary Tract Infections among Sudanese Patients. *British Microbiology Research Journal.* 2012; 2(2): 53-61.
 29. Festo E, Kidenya BR, Hokororo A, Mshana SE. Predictors of urinary tract infection among febrile children attending at Bugando Medical Centre, Northwestern Tanzania. *Archives Clin Microbiol.* 2011; 2(5), doi:10:3823/239.
 30. Gallegos JI, Márquez S, Morales K, Peña A. Etiologic and antibiotic susceptibility profile of the first episode of febrile urinary tract infection. *Rev Chilena Infectol.* 2013 Oct; 30(5): 474-479..
 31. Bouskraoui M1, Ait Sab I, Draiss G, Bourrouss M, Sbihi M. Epidemiology of urinary tract infection in children in Marrakech. *Arch Pediatr.* 2010 Sep; 17, Suppl 4: S177-178.
 32. Ahmad S. Pattern of urinary tract infection in Kashmir and antimicrobial susceptibility. *Bangladesh Med Res Counc Bull.* 2012 Dec; 38(3): 79-83.
 33. Ada-Adegbola HO1, Muili KA. Antibiotic susceptibility pattern of urinary tract pathogens in Ibadan, Nigeria. *Afr J Med Med Sci.* 2010 Sep; 39(3): 173-179.
 34. Jombo GT1, Jonah P, Ayeni JA. Multiple resistant *Pseudomonas aeruginosa* contemporary medical practice: findings from urinary isolates at a Nigerian University Teaching Hospital. *Niger J Physiol Sci.* 2008 Jun-Dec; 23(1-2): 105-109.
 35. Sader HS, Flamm RK, Jones RN. Frequency of occurrence and antimicrobial susceptibility of Gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals. *J Chemother.* 2013 Aug 5. [Epub ahead of print].



International Medical Informatics Association

- Home
- About IMIA
- Contact Us
- Members
- Member Services
- Governance
- Working Groups and Special Interest Groups
- Taskforces
- Publications
- IMIA Endorsed Documents
- IMIA Award of Excellence
- Strategic Plan
- MedInfo
- Events
- dataforhealth initiative
- IMIA Accreditation (pilot)
- Login

The IMIA Vision

The International Medical Informatics Association (IMIA) is the world body for health and biomedical informatics. As an 'association of associations', IMIA acts as a bridging organisation, bringing together the constituent organisations and their members. IMIA provides leadership and expertise to the multidisciplinary, health focused community and to policy makers, to enable the transformation of healthcare in accord with the world-wide vision of improving the health of the world population.

» Read More

Latest news updates

François Grémy, First IMIA President, Passed Away (<http://wp.me/pvCUS-1Zm>)

It is with regret that we announce that Prof. François Grémy, one of the founders of IMIA and its first President, has passed away. His close colleague Prof. Patrice Degoulet writes: "It is with a great emotion and sadness that I inform you that François Grémy passed on July 22, 2014 at the age of 86. As founder of IFIP TC4 that gave rise to IMIA he is considered to be the IMIA father and a key European figure in the field. All those that have the chance to meet him recognize his kindness, his deep humanism and his brilliant character and brain."


Sedick Isaacs Award - 2014 Call for Nominations Open Until 15 August (<http://wp.me/pvCUS-1XW>)

The Sedick Isaacs Award is a newly-inaugurated IMIA Award that recognises the lasting contribution made to health and medical informatics in Africa by Dr Sedick Isaacs. It is an IMIA award, funded by IMIA and administered jointly by IMIA and HELINA. Nominations should be submitted no later than 15 August, 2014. See <http://wp.me/pvCUS-1XW>

Next IMIA GA Meeting


IMIA General Assembly 2014
Wed, 28/08/2013 - 00:00

The 2014 IMIA General Assembly will be held on 31 October 2014 in New Delhi, India in conjunction with APAMI2014 conference (www.apami2014.com)



MIE 2014
31.08 - 03.09.2014
Istanbul

Let's Meet Where the Continents Meet



www.mie2014.org

